Biomarker Research Services Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biomarker Research Services Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Biomarkers are widely used in development of drugs. One of the primary processes through which biomarkers are accepted for use in drug development, is the drug approval process. The biomarker is included in the regulatory submission process for drug approval such as Investigational New Drug (IND), Biologics License Disease Indications (BLA), or New Drug Disease Indication (NDA), and are then accepted for use in that specific drug development program. Another process through which biomarkers are accepted for use in drug development is the Biomarker Qualification Program (BQP), which qualifies a biomarker for a particular context of use (COU), independent of a drug approval submission. This pathway is intended for biomarkers that are used in multiple drug development programs. Qualified biomarkers have the potential to offer valuable information that may help during drug development.
Market Dynamics
Factors such as increasing initiatives for development of precision medicine, increasing prevalence of chronic diseases, and increasing demand for development of companion diagnostics, is supporting the growth of global biomarker research services market. For instance, in 2021, National Institutes of Health launched Precision Medicine Initiative (PMI) with an investment of US$ 215 million to accelerate biomedical research and offer clinicians new tools to select therapies that can be used in a more individualized approach with patients. Moreover, potential of biomarkers in disease diagnosis, and in companion diagnostics is expected to boost global biomarker research services market growth. Organizations such as Covance, Inc., Charles River, and others are actively involved in providing biomarker research services.
Key features of the study:
This report provides in-depth analysis of global biomarker research services market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global biomarker research services market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key companies covered as a part of this study include Noble Life Sciences, Inc., Reprocell Corporation, Coriell Institute, BioIVT, ICON Plc., SRI International, Inc., Charles River Laboratories, Inc., Nordic Bioscience A/S, Proteome Sciences Plc., and Covance Inc. (Laboratory Corporation of America Holdings, Inc.)
Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global biomarker research services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global biomarker research services market
Detailed Segmentation:
Global Biomarker Research Services Market, By Service Type:
Biomarker Research Services
CDx Research Services
Global Biomarker Research Services Market, By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
Global Biomarker Research Services Market, By Region:
North America
By Service Type:
Biomarker Research Services
CDx Research Services
By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
By Country:
U.S.
Canada
Europe
By Service Type:
Biomarker Research Services
CDx Research Services
By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Service Type:
Biomarker Research Services
CDx Research Services
By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Service Type:
Biomarker Research Services
CDx Research Services
By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Service Type:
Biomarker Research Services
CDx Research Services
By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Service Type:
Biomarker Research Services
CDx Research Services
By Disease Indication:
Oncology
Cardiovascular Disorder
Infectious Disease
Neurological Disorder
Immunological Disorder
Others
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Noble Life Sciences, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
REPROCELL Corporation
Coriell Institute
BioIVT
ICON Plc.
SRI International
Charles River Laboratories, Inc.
Nordic Bioscience A/S
Proteome Sciences Plc.
Covance Inc. (Laboratory Corporation of America Holdings, Inc.)
“*” marked represents similar segmentation in other categories in the respective section.